Alteration in Quality of Life of CF Patients, Following Change of Treatment From Antibiotic Inhalation to Antibiotic Inhaler
Conditions
Keywords
Cystic Fibrosis, Chronic Pseudomonas Infection, Inhaled Tobramycin
Brief summary
Pseudomonas is a common and virulent respiratory bacteria in patients with Cystic Fibrosis (CF). With time, the infection with Pseudomonas becomes chronic and very difficult to eradicate. The standard treatment of chronic Pseudomonas infection is inhaled Tobramycin which is given every other month.. Inhalation of Tobramycin was proven as an effective treatment that improves the respiratory function and reduces the concentration of bacteria in the sputum. However, inhaled treatment lasts between 15 to 30 minutes twice a day and therefore adherence is a major problem. The effect of switching from inhalation treatment to inhaler treatment on patient's adherence and quality of life has not been studied.
Interventions
None listed
Sponsors
Sheba Medical Center
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
6 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age 6 years and above, Chronic Pseudomonas infection
Exclusion criteria
* Younger than 6 years; No chronic PSeudomonas infection
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement in quality of life | 1 year |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Difference in exacerbation events | 1 year | To be measured by: Worsening of CF symptoms such as coughing, sputum, deterioration in FEV1, all of which require hospitalization |
Countries
Israel
Contacts
Primary ContactOri Sarouk, MD
Outcome results
None listed